Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy

To the Editor We read with interest the study of Hank et al, which proposes that there is a decreased risk of developing clinically relevant pancreatic fistula (CR-POPF) when neoadjuvant chemotherapy (NAT) therapy is applied for pancreatic adenocarcinoma. They suggest induction of fibrosis of the pancreatic gland as a proposed mechanism. While the data appear intriguing, there are some methodologic issues that raise questions.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research